Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Impact · against what's priced in

Cogent Biosciences (COGT) receives a significant valuation catalyst from positive Phase 3 data and a confirmed PDUFA date for its GIST combination therapy. The transition from experimental data to a Priority Review timeline and the expansion into first-line treatment meaningfully increase the company's projected addressable market.

COGT+0.90

No priced-in read yet